Inventor · disambiguated record
Stephen Douglas Barrett
Also filed as: BARRETT STEPHEN · BARRETT STEPHEN D · BARRETT STEPHEN DOUGLAS
43 granted patents·15 pending applications·1,043 citations·filing 1993–2022
98Inventor score
Files withWARNER LAMBERT CO21CAYMAN CHEMICAL CO INC20PFIZER5THESAN PHARMACEUTICALS INC3RECOVERY THERAPEUTICS INC2
Top patents by PatentIndex Score
58 records- 0198US6310060B12-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitorsWARNER LAMBERT CO·Filed 1998·Granted Oct 30, 2001·146 cites·37 claims
- 0297US7169816B24-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitorsWARNER LAMBERT CO·Filed 2005·Granted Jan 30, 2007·30 cites·16 claims
- 0397US6821963B24-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitorsWARNER LAMBERT CO·Filed 2002·Granted Nov 23, 2004·52 cites·21 claims
- 0496US6469004B1Benzoheterocycles and their uses as MEK inhibitorsWARNER LAMBERT CO·Filed 2000·Granted Oct 22, 2002·134 cites·44 claims
- 0595US6506798B14-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitorsWARNER LAMBERT CO·Filed 1999·Granted Jan 14, 2003·103 cites·46 claims
- 0694US6960614B2Oxygenated esters of 4-lodo phenylamino benzhydroxamic acidsWARNER LAMBERT CO·Filed 2001·Granted Nov 1, 2005·89 cites·5 claims
- 0794US6750217B2Benzenesulfonamide derivatives and their use as MEK inhibitorsWARNER LAMBERT CO·Filed 2002·Granted Jun 15, 2004·63 cites·3 claims
- 0893US7019033B22-(4-bromo or 4-iodo phenylamino) benzoic acid derivativesWARNER LAMBERT CO·Filed 2002·Granted Mar 28, 2006·26 cites·11 claims
- 0991US6440966B1Benzenesulfonamide derivatives and their use as MEK inhibitorsWARNER LAMBERT CO·Filed 1999·Granted Aug 27, 2002·94 cites·40 claims
- 1090US7411001B2Oxygenated esters of 4-iodo phenylamino benzhydroxamic acidsWARNER LAMBERT CO·Filed 2005·Granted Aug 12, 2008·23 cites·21 claims
- 1190US7030119B1Method for treating chronic pain using MEK inhibitorsWARNER LAMBERT CO·Filed 2000·Granted Apr 18, 2006·45 cites·28 claims
- 1289US6891066B2N-(4-substituted phenyl)-anthranilic acid hydroxamate estersWARNER LAMBERT CO·Filed 2003·Granted May 10, 2005·33 cites·19 claims
- 1388US6545030B11-heterocycle substituted diarylaminesWARNER LAMBERT CO·Filed 1999·Granted Apr 8, 2003·78 cites·42 claims
- 1487US7078438B2N-(4 substituted phenyl)-anthranilic acid hydroxamate estersWARNER LAMBERT CO·Filed 2005·Granted Jul 18, 2006·12 cites·10 claims
- 1587US6492363B22-(4-bromo or 4-iodo phenylamino) benzoic acid derivativesWARNER LAMBERT CO·Filed 2001·Granted Dec 10, 2002·14 cites·35 claims
- 1686US9487478B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2015·Granted Nov 8, 2016·4 cites·21 claims
- 1785US9180116B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2013·Granted Nov 10, 2015·6 cites·20 claims
- 1882US9440919B2Difluorolactam compositions for EP4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2013·Granted Sep 13, 2016·4 cites·23 claims
- 1981US6770778B2N-(4-substituted phenyl)-anthranilic acid hydroxamate estersPFIZER·Filed 2003·Granted Aug 3, 2004·16 cites·35 claims
- 2080US9701630B2Difluorolactam compositions for EP4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2016·Granted Jul 11, 2017·2 cites·20 claims
- 2180US9260450B2Therapeutic pyrazolyl thienopyridinesTHESAN PHARMACEUTICALS INC·Filed 2015·Granted Feb 16, 2016·2 cites·12 claims
- 2278US7964612B2Therapeutic pyrazolyl thienopyridinesGRACEWAY PHARMACEUTICALS LLC·Filed 2007·Granted Jun 21, 2011·2 cites·12 claims
- 2377US11884624B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2021·Granted Jan 30, 2024·0 cites·3 claims
- 2477US8455512B2Therapeutic pyrazolyl thienopyridinesBARRETT STEPHEN D·Filed 2011·Granted Jun 4, 2013·4 cites·11 claims
- 2577US5534522A(R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agentWARNER LAMBERT CO·Filed 1995·Granted Jul 9, 1996·23 cites·6 claims
- 2676US5346911AAzabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatmentWARNER LAMBERT CO·Filed 1993·Granted Sep 13, 1994·17 cites·12 claims
- 2773US11066361B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2020·Granted Jul 20, 2021·0 cites·3 claims
- 2872US8536185B2Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseasesENDRES GREGORY W·Filed 2009·Granted Sep 17, 2013·2 cites·57 claims
- 2967US10556862B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2018·Granted Feb 11, 2020·0 cites·4 claims
- 3066US11345690B2Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2019·Granted May 31, 2022·0 cites·3 claims
- 3162US9120820B2Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteinsBARRETT STEPHEN DOUGLAS·Filed 2012·Granted Sep 1, 2015·1 cites·7 claims
- 3261US9090625B2Therapeutic pyrazolyl thienopyridinesTHESAN PHARMACEUTICALS INC·Filed 2013·Granted Jul 28, 2015·0 cites·18 claims
- 3360US9914725B2Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2014·Granted Mar 13, 2018·0 cites·4 claims
- 3459US7799823B2Androgen modulatorsWARNER LAMBERT CO·Filed 2006·Granted Sep 21, 2010·0 cites·10 claims
- 3559US2017066751A1Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2016·Application pending·0 cites
- 3658US9126973B2Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseasesCAYMAN CHEMICAL CO INC·Filed 2014·Granted Sep 8, 2015·0 cites·51 claims
- 3758US6251943B1Method of treating or preventing septic shock by administering a MEK inhibitorWARNER LAMBERT CO·Filed 1997·Granted Jun 26, 2001·18 cites·9 claims
- 3858US2024173311A1Methods and compositions for modulating fgf activityRECOVERY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3958US2024174631A1Compounds, compositions, and methods for modulating fgf activityRECOVERY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4057US9938289B2Therapeutic pyrazolyl thienopyridinesTHESAN PHARMACEUTICALS INC·Filed 2016·Granted Apr 10, 2018·0 cites·17 claims
- 4155US7470715B2Estrogen modulatorsPFIZER·Filed 2006·Granted Dec 30, 2008·0 cites·5 claims
- 4255US2009131397A1Estrogen modulatorsPFIZER·Filed 2008·Application pending·0 cites
- 4355US2019144435A1Difluorolactam compositions for ep4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2019·Application pending·0 cites
- 4454US2005049429A14-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitorsFiled 2004·Application pending·0 cites
- 4554US2018170918A1Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2018·Application pending·0 cites
- 4653US2017260173A1Difluorolactam compositions for ep4-mediated osteo related diseases and condtionsCAYMAN CHEMICAL CO INC·Filed 2017·Application pending·0 cites
- 4753US2013079375A1Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseasesCAYMAN CHEMICAL CO INC·Filed 2012·Application pending·0 cites
- 4852US7674819B2Androgen modulatorsWARNER LAMBERT CO·Filed 2006·Granted Mar 9, 2010·0 cites·16 claims
- 4949US10729810B2Methods, systems, and compositions for promoting bone growthCAYMAN CHEMICAL CO INC·Filed 2014·Granted Aug 4, 2020·0 cites·16 claims
- 5047US9676712B2Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2014·Granted Jun 13, 2017·0 cites·24 claims
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Stephen Douglas Barrett files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →